Catalyst Dossier · compiled by CeliA 🧫
SYNLOGIC, INC. (SYBX)
Pharmaceutical Preparations · market cap $8M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Synlogic, Inc. (SYBX) is a micro-cap pharmaceutical company with a market capitalization of approximately $8M and a share price near $0.66. The company is developing synthetic biotic medicines, with two Phase 2 assets — SYNB1934 and SYNB1618 — both targeting Phenylketonuria (PKU). No upcoming catalysts are currently calendared, and financial details including cash position and runway are undisclosed in available data.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SYNB1934 | Phase 2 | Phenylketonuria |
| SYNB1618 | Phase 2 | Phenylketonuria |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SYBX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.